Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
about
Clinical Validation of Therapeutic Drug Monitoring of Imipenem in Spent Effluent in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Pilot StudyAntibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunctionMeropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.Delivering precision antimicrobial therapy through closed-loop control systems.Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy.Factors affecting serum concentration of vancomycin in critically ill oliguric pediatric patients receiving continuous venovenous hemodiafiltration.Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and VaborbactamPharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
P2860
Q28551453-B27A9EDD-B281-4D2C-9C68-2ECB43C9975AQ33821972-9AEE3561-C2DD-488D-9D62-34B0DEC3A787Q35819409-03A709AD-2DB5-46C0-A206-09DA253ED8A0Q35960694-8AB51CB4-EB73-43E4-B360-7A8B6D84C54DQ39882067-884756E7-365F-4F76-9A87-DD3EB5AA0BB4Q40234980-7F5E2E56-94B2-47E0-A422-99B8BD067610Q40445718-9591BCF8-B698-4704-8962-69C814E82F40Q47276911-E0E9009B-8E7B-4541-9D37-036D516BEE5BQ50260879-4DF11163-12B8-46F3-916B-A4E289F3D6D9Q52807819-A39D31C9-27FD-4B05-8A21-400CC045C106Q55463665-691DA5CB-6B20-448A-A122-B84EEABB3AE0Q58701126-41E1E696-4932-4F35-A9A2-A68988AE5456Q58701649-D7E57AE0-527D-4DA0-A737-3B85309D54D3
P2860
Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Beta-lactam dosing in critical ...... ous renal replacement therapy.
@ast
Beta-lactam dosing in critical ...... ous renal replacement therapy.
@en
type
label
Beta-lactam dosing in critical ...... ous renal replacement therapy.
@ast
Beta-lactam dosing in critical ...... ous renal replacement therapy.
@en
prefLabel
Beta-lactam dosing in critical ...... ous renal replacement therapy.
@ast
Beta-lactam dosing in critical ...... ous renal replacement therapy.
@en
P2093
P2860
P921
P356
P1433
P1476
Beta-lactam dosing in critical ...... ous renal replacement therapy.
@en
P2093
Dolors Soy
Gonzalo Calvo
Ignacio Martín-Loeches
Marta Ulldemolins
Sergi Vaquer
P2860
P2888
P356
10.1186/CC13938
P5008
P577
2014-06-23T00:00:00Z
P5875
P6179
1042546210